Polarized dendritic cells as cancer vaccines: Directing effector-type T cells to tumors

This publication has 141 references indexed in Scilit:

• Generation and maintenance of memory CD4+ T Cells
  Current Opinion in Immunology, 2009
• Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines
  Cancer Immunology, Immunotherapy, 2009
• IL‐4 inhibits VLA‐4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit
  European Journal of Immunology, 2008
• Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration
  Cancer Immunology, Immunotherapy, 2008
• Role of chemokines in tumor growth
  Cancer Letters, 2007
• DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27
  Nature Immunology, 2007
• Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice
  Proceedings of the National Academy of Sciences, 2006
• Regulatory T cells, tumour immunity and immunotherapy
  Nature Reviews Immunology, 2006
• Mechanisms and functional significance of tumour-induced dendritic-cell defects
  Nature Reviews Immunology, 2004
• The promise of cancer vaccines
  Nature Reviews Cancer, 2004